Dr. Subbiah and Dr. Lukas review the efficacy and safety data from key clinical trials like ROAR and MATC evaluating tumor agnostic therapies across different tumor types.
Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC
TAR-210 Demonstrates Preliminary Efficacy in FGFR-Altered Non–Muscle-Invasive Bladder Cancer
Dr Kutikov on Therapeutic Approaches in Urothelial Cancer Requiring Cystectomy
Dr Li on the Rationale of the MoonRISe-1 Trial in NMIBC